Congratulations to Richard Berry, PhD, who was recently promoted to Vice President, Biotherapeutics! At oNKo-Innate, Richard has used his knowledge of protein chemistry and structural biology to take the lead on our protein engineering platform, developing innovative biotherapeutics for the treatment of cancer. Richard has an impressive depth and breadth of knowledge of immune cell receptors, and his previous research has been key in furthering our understanding of natural killer cell activation.
Combined with our functional genomics and computational platforms, Richard’s strong knowledge of immune biology has allowed us to prosecute some of the boldest targets in immuno-oncology He has also demonstrated strong leadership and driven engagement across the broader oNKo-Innate team, generating new ideas and implementing cutting-edge technologies.
As VP, Biotherapeutics, Richard will work in collaboration with our CSO and CTO to formulate strategies that advance our pipeline assets through discovery and pre-clinical development, into clinical trials. With Richard on the team, we’re confident we can transform our discoveries into effective cancer therapies.
Congratulations, Richard – thanks for your enthusiasm, incredible expertise, and willingness to tackle new obstacles!